Foghorn Therapeutics Inc. Income Statement

Income Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.54M0.43M1.32M19.23M34.16M22.60M
Gross Profit -0.54M0.43M1.32M19.23M34.16M22.60M
Operating items
Research & Development 44.36M57.72M80.33M105.62M109.69M94.53M
Selling, General & Administrative 6.72M11.25M21.73M30.75M32.37M28.36M
Other Operating Expenses 2.40M
Operating Expenses 51.08M68.96M102.05M136.37M142.06M125.28M
Operating Income -51.08M-68.53M-100.73M-117.14M-107.91M-102.68M
EBIT -51.08M-68.53M-100.73M-117.14M-107.91M-102.68M
Non-operating items
Interest & Investment Income 0.06M5.67M10.88M11.90M
Other Non Operating Income 0.49M1.00M2.49M2.58M2.83M4.16M
Non Operating Income -0.04M-0.27M2.49M8.26M13.71M16.06M
Net income details
EBT -51.62M-69.51M-102.58M-108.88M-94.20M-86.62M
Tax Provisions 4.23M
Profit After Tax -51.13M-68.80M-101.32M-108.90M-98.43M-86.62M
Income from Continuing Operations -51.62M-69.51M-102.58M-108.88M-98.43M-86.62M
Consolidated Net Income -51.62M-69.51M-102.58M-108.88M-98.43M-86.62M
Income towards Parent Company -51.62M-69.51M-102.58M-108.88M-98.43M-86.62M
Net Income towards Common Stockholders -51.62M-69.51M-102.58M-108.88M-98.43M-86.62M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 35.69M35.81M37.09M41.80M42.22M55.59M
Shares Outstanding (Diluted Average) 11.05M37.17M41.59M41.97M54.90M
EBITDA -51.13M-68.81M-101.32M-112.86M-95.27M-85.66M